Logo image of IDP.DE

BIOGEN INC (IDP.DE) Stock Price, Quote, News and Overview

FRA:IDP - Deutsche Boerse Ag - US09062X1037 - Common Stock - Currency: EUR

109.85  -0.1 (-0.09%)

IDP.DE Quote, Performance and Key Statistics

BIOGEN INC

FRA:IDP (8/8/2025, 7:00:00 PM)

109.85

-0.1 (-0.09%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High186.85
52 Week Low99
Market Cap16.10B
Shares146.53M
Float146.22M
Yearly DividendN/A
Dividend YieldN/A
PE7.99
Fwd PE8.12
Earnings (Next)10-28 2025-10-28/bmo
IPO09-17 1991-09-17


IDP.DE short term performance overview.The bars show the price performance of IDP.DE in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -5 -10 -15

IDP.DE long term performance overview.The bars show the price performance of IDP.DE in the last 1, 2 and 3 years. 1 year 2 years 3 years -10 -20 -30 -40 -50

The current stock price of IDP.DE is 109.85 EUR. In the past month the price decreased by -3.68%. In the past year, price decreased by -40.44%.

BIOGEN INC / IDP Daily stock chart

IDP.DE Competitors/Peers

The largest stocks on the EU markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
4AB.DE ABBVIE INC 18.64 299.58B
AMG.DE AMGEN INC 13.77 132.01B
GIS.DE GILEAD SCIENCES INC 15.46 127.88B
VX1.DE VERTEX PHARMACEUTICALS INC N/A 81.12B
1REGN.MI REGENERON PHARMACEUTICALS 12.43 52.62B
ARGX.BR ARGENX SE 76.6 34.79B
22UA.DE BIONTECH SE-ADR N/A 23.13B
1BIIB.MI BIOGEN INC 8.37 16.66B
1MRNA.MI MODERNA INC N/A 8.76B
0QF.DE MODERNA INC N/A 8.73B
ABVX.PA ABIVAX SA N/A 4.54B
1VKTX.MI VIKING THERAPEUTICS INC N/A 3.31B

About IDP.DE

Company Profile

IDP logo image Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 7,605 full-time employees. The firm is focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. The company operates a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). The company is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS, and FUMADERM for the treatment of severe plaque psoriasis. The company also collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of Postpartum Depression (PPD).

Company Info

BIOGEN INC

225 Binney Street

Cambridge MASSACHUSETTS US

Employees: 7605

IDP Company Website

IDP Investor Relations

Phone: 17814642000

BIOGEN INC / IDP.DE FAQ

What is the stock price of BIOGEN INC today?

The current stock price of IDP.DE is 109.85 EUR. The price decreased by -0.09% in the last trading session.


What is the ticker symbol for BIOGEN INC stock?

The exchange symbol of BIOGEN INC is IDP and it is listed on the Deutsche Boerse Ag exchange.


On which exchange is IDP.DE stock listed?

IDP.DE stock is listed on the Deutsche Boerse Ag exchange.


What is the price forecast or stock price prediction for BIOGEN INC stock?

43 analysts have analysed IDP.DE and the average price target is 152.87 EUR. This implies a price increase of 39.17% is expected in the next year compared to the current price of 109.85. Check the BIOGEN INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is BIOGEN INC worth?

BIOGEN INC (IDP.DE) has a market capitalization of 16.10B EUR. This makes IDP.DE a Large Cap stock.


How many employees does BIOGEN INC have?

BIOGEN INC (IDP.DE) currently has 7605 employees.


What are the support and resistance levels for BIOGEN INC (IDP.DE) stock?

BIOGEN INC (IDP.DE) has a support level at 104.69 and a resistance level at 110.47. Check the full technical report for a detailed analysis of IDP.DE support and resistance levels.


Is BIOGEN INC (IDP.DE) expected to grow?

The Revenue of BIOGEN INC (IDP.DE) is expected to decline by -3.89% in the next year. Check the estimates tab for more information on the IDP.DE EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy BIOGEN INC (IDP.DE) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does BIOGEN INC (IDP.DE) stock pay dividends?

IDP.DE does not pay a dividend.


When does BIOGEN INC (IDP.DE) report earnings?

BIOGEN INC (IDP.DE) will report earnings on 2025-10-28, before the market open.


What is the Price/Earnings (PE) ratio of BIOGEN INC (IDP.DE)?

The PE ratio for BIOGEN INC (IDP.DE) is 7.99. This is based on the reported non-GAAP earnings per share of 13.75 and the current share price of 109.85 EUR. Check the full fundamental report for a full analysis of the valuation metrics for IDP.DE.


IDP.DE Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

IDP.DE Fundamental Analysis

ChartMill assigns a fundamental rating of 5 / 10 to IDP.DE. While IDP.DE belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

IDP.DE Financial Highlights

Over the last trailing twelve months IDP.DE reported a non-GAAP Earnings per Share(EPS) of 13.75. The EPS decreased by -3.61% compared to the year before.


Industry RankSector Rank
PM (TTM) 15.07%
ROA 5.28%
ROE 8.71%
Debt/Equity 0.27
Chartmill High Growth Momentum
EPS Q2Q%3.6%
Sales Q2Q%7.33%
EPS 1Y (TTM)-3.61%
Revenue 1Y (TTM)-1.62%

IDP.DE Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 73% to IDP.DE. The Buy consensus is the average rating of analysts ratings from 43 analysts.

For the next year, analysts expect an EPS growth of -7.3% and a revenue growth -3.89% for IDP.DE


Ownership
Inst Owners92.86%
Ins Owners0.13%
Short Float %N/A
Short RatioN/A
Analysts
Analysts73.02
Price Target152.87 (39.16%)
EPS Next Y-7.3%
Revenue Next Year-3.89%